<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317301</url>
  </required_header>
  <id_info>
    <org_study_id>HL_HL151_302</org_study_id>
    <nct_id>NCT03317301</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus</brief_title>
  <official_title>a Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      a Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase Ⅲ Study to
      Evaluate the Efficacy and Safety of HL151 versus Talion Tab. in Pruritus cutaneus.

      - Endpoint: VAS Score Change, Investigator's assessment of overall treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in VAS(Visual Analogue Scale) score at 2nd week after clinical drug administration compared to baseline</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)</time_frame>
    <description>VAS score: 0 Point ~ 10 Point (asymptomatic ~ Maximum pruritus) Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in VAS(Visual Analogue Scale) score at 1st week after clinical drug administration</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (1 week)</time_frame>
    <description>VAS score: 0 Point ~ 10 Point (asymptomatic ~ Maximum pruritus)
Evaluation period: Visit 2 (0 week), Visit 3 (1 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VAS(Visual Analogue Scale) score at 1st and 2nd week(Day) after clinical drug administration compared to baseline</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks</time_frame>
    <description>VAS score: 0 Point ~ 10 Point (asymptomatic ~ Maximum pruritus)
Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VAS(Visual Analogue Scale) score at 1st and 2nd week after clinical drug administration compared to baseline</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)</time_frame>
    <description>VAS score: 0 Point ~ 10 Point (asymptomatic ~ Maximum pruritus)
Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's assessment of overall treatment(Cochran-Mantel-Haenszel method)</measure>
    <time_frame>Visit 4 (2 weeks)</time_frame>
    <description>VAS score: 0 Point ~ 10 Point (asymptomatic ~ Maximum pruritus)
Evaluation period: Visit 4 (2 weeks)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL151</intervention_name>
    <description>2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talion Tab</intervention_name>
    <description>2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)</description>
    <arm_group_label>Active comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both gender, 19 years ≤ age

          2. Patients with pruritus due to the following diseases

             ① acute eczema, chronic eczema, monetary eczema, sebaceous deficiency eczema

             ② contact dermatitis, atopic dermatitis, seborrheic dermatitis, neurodermatitis

             ③ Acute prurigo (Strofus, Urticaria, lichen urticatus), subacute prurigo, chronic
             prurigo (nodular prurigo)

             ④ systemic skin pruritus, focal skin pruritus

          3. In visit 2, during the run-in period previous week the VAS score of day and night time
             were 2 or more average points per day (maximum 4 points)

          4. Those who can ability to record subject diary

          5. Written consent voluntarily to participate in this clinical trial after understanding
             and detailed explanation about this clinical trial

        Exclusion Criteria:

          1. Patients with pruritus due other medical causes (liver disease, heart failure, etc.)

          2. Among patients with skin disease, malignant tumors and patients with chronic urticaria
             skin disease

          3. Patients with systemic infection symptoms at the time of clinical trials

          4. Asthmatic patients requiring steroid treatment

          5. Patients with Spastic diseases such as epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seona Sin, CRC</last_name>
    <phone>821086255683</phone>
    <email>seona135790@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Na Hyun Kang, CRA</last_name>
    <email>nahyun.kang@hanlim.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hanyang Univ. Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <state>Kyeonggi-do</state>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seona Sin, CRC</last_name>
      <email>seona135790@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jung Soo Kim, PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pruritus cutaneus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

